{"id":"W2980850490","doi":"10.1200/po.19.00221","title":"Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"National Cancer Institute; Sanofi; Servier; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Fibroblast growth factor receptor 1; Tolerability; Medicine; Fibroblast growth factor receptor; Cancer; Breast cancer; Oncology; Internal medicine; Cancer research; Pharmacology; Receptor; Adverse effect; Fibroblast growth factor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009657351,0.0008465971,0.001720517,0.0004349343,0.0002676415,0.0006368194,0.0004865484,0.0003803631,0.001096909],"category_scores_gemma":[0.0005818448,0.0002820362,0.0008097794,0.0005064891,0.0003832558,0.0005257326,0.0004017069,0.001200606,0.0002839161],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008603291,"about_ca_system_score_gemma":0.0007392854,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006649294,"about_ca_topic_score_gemma":0.002924153,"domain_scores_codex":[0.9995055,0.0001527544,0.0000563932,0.0001063276,0.00007919385,0.00009978672],"domain_scores_gemma":[0.9997613,0.00003423013,0.00005604948,0.00002581092,0.00001769695,0.0001049705],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3285461,0.01685985,0.04237416,0.001103639,0.002898191,0.001164792,0.0005716823,0.01094651,0.1500601,0.0004897206,0.002806759,0.4421785],"study_design_scores_gemma":[0.1886079,0.6189846,0.09272242,0.000105806,0.002726685,0.004344109,0.000278275,0.01021685,0.0700037,0.0006460702,0.01124096,0.0001225901],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955499,0.002257326,0.0003642337,0.0001731806,0.0000341633,0.0002933541,0.0001490685,0.00005456671,0.001124208],"genre_scores_gemma":[0.9981585,0.0005029057,0.0006267101,0.00007611772,0.00003008409,0.0001193942,0.0001764229,0.000005241614,0.0003045365],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001720517,"threshold_uncertainty_score":0.006242156,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007405147188545542,"score_gpt":0.2759090181197813,"score_spread":0.2685038709312357,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}